eFFECTOR's Cancer Therapy Achieves Two Partial Responses In Early-Stage Study

eFFECTOR's Cancer Therapy Achieves Two Partial Responses In Early-Stage Study
  • eFFECTOR Therapeutics Inc's EFTR ongoing Phase 1/2 trial of zotatifin in solid tumors showed early signals of clinical activity in two patients with breast cancer. 
  • As of the cutoff date of March 4, interim results showed that treatment-emergent adverse events related to zotatifin were primarily mild, readily managed, and reversible.
  • One patient with amplified Cyclin D1 and an ESR1 mutation, who had progressed on prior treatment with fulvestrant, experienced a confirmed partial response on zotatifin/fulvestrant combo.
  • Related: eFFECTOR Secures $50M Funding From Lincoln Park Capital.
  • A second partial response was observed with zotatifin, fulvestrant, and abemaciclib in a patient with PIK3CA mutations. 
  • Modulation of protein translation by zotatifin was highly selective, with less than 1% of protein expression altered. Patients treated with zotatifin demonstrated reductions in the expression of key oncogenic drivers.
  • The company anticipates topline data from current expansion cohorts by the end of 2022, and initial overall response rate data from the Cyclin D1 amplified ER+ breast cancer cohort in 1H of 2023.
  • eFFeCTOR expanded the cohort evaluating zotatifin/ fulvestrant combo in ER+ breast cancer patients to 18 patients. 
  • A new cohort evaluating zotatifin combined with fulvestrant in ER+ breast cancer patients with Cyclin D1 amplification is being planned.
  • Price Action: EFTR shares closed 10% lower at $1.79 on Friday.

Posted In: BriefsPhase 1 TrialBiotechNewsPenny StocksHealth CareGeneral